Improve access. Improve life.
The End Drug Shortages Alliance is a collaboration of select health system, supply chain, industry and other stakeholders dedicated to solving pharmaceutical supply challenges by increasing transparency. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve measured results that improve access to essential medications and improve quality of life for patients that rely on these medications.
Commitment to supply resiliency
As part of the ongoing strategy to end supply interruptions, the Vizient® team of pharmacy experts have identified essential medications that if not available, could represent the greatest threat to providing immediate and high-quality patient care. As of this edition, 15 drugs were added to the list creating a total of 265 line items, representing 251 unique drugs.
Complete the form to download and view these essential medications which are grouped in the three categories below.
- Acute treatment drugs with no alternatives (77 drugs)
- Chronic treatment drugs with no alternatives (37 drugs)
- High impact drugs (151 drugs)
- Pediatric impact (68 drugs)
- Antibiotic resistance (28 drugs)
Quantifying drivers of supply chain resilience in pediatric oncology medications
Angels for Change, United States Pharmacopeia (USP) and Vizient collaborated to characterize and quantify supply chain risk for drugs to improve pediatric oncology access to quality medicines.Download the white paper
Understanding and mitigating pediatric drug shortages
Vizient pharmacy experts, in collaboration with the Children’s Hospital Association (CHA), have created a report examining the impact of drug shortages on self-governed pediatric hospitals, and the strategies employed to manage and mitigate these shortages.
Download the report
Connect with Vizient to find out how we can help you manage drug shortages or to learn about our other pharmacy initiatives.